Product Name:

NebuPeptide™ Lutetium (177Lu) oxodotreotide (Peptide Reference)

Catalog Number:

NBS-233775

Description:

NebuPeptide™ Lutetium (177Lu) oxodotreotide (Peptide Reference)(CAT#NBS-233775) is synthesized in accordance with the Lutetium (177Lu) oxodotreotide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Insulin Aspart/Insulin Degludec reference peptide ranging from milligrams to kilograms.

Peptide Name:

Lutetium (177Lu) oxodotreotide

Background:

Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. It is a radiolabeled somatostatin analog. Alternatives to 177Lu-dotatate include yttrium-90 dotatate or DOTATOC. The longer range of the beta particles emitted by 90Y, which deliver the therapeutic effect, may make it more suitable for large tumors with 177Lu reserved for smaller volume. The US Food and Drug Administration (FDA) considers 177Lu dotatate to be a first-in-class medication.

Alias:

N/A

CAS Number:

437608-50-9

Formula:

C65H87LuN14O19S2

Molecular Weight:

1607.58

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.